Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.
Zhang Z, Shahinfar S, Keane WF, Ramjit D, Dickson TZ, Gleim GW, Mogensen CE, de Zeeuw D, Brenner BM, Snapinn SM. Zhang Z, et al. Among authors: shahinfar s. J Am Soc Nephrol. 2005 Jun;16(6):1775-80. doi: 10.1681/ASN.2004080632. Epub 2005 May 4. J Am Soc Nephrol. 2005. PMID: 15872078
Losartan and end-organ protection--lessons from the RENAAL study.
Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM; RENAAL Investigators. Kowey PR, et al. Among authors: shahinfar s. Clin Cardiol. 2005 Mar;28(3):136-42. doi: 10.1002/clc.4960280307. Clin Cardiol. 2005. PMID: 15813620 Free PMC article. Clinical Trial.
Losartan: lessons learned from the RENAAL study.
Shahinfar S, Lyle PA, Zhang Z, Keane WF, Brenner BM. Shahinfar S, et al. Expert Opin Pharmacother. 2006 Apr;7(5):623-30. doi: 10.1517/14656566.7.5.623. Expert Opin Pharmacother. 2006. PMID: 16553578 Review.
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D. Eijkelkamp WB, et al. Among authors: shahinfar s. J Am Soc Nephrol. 2007 May;18(5):1540-6. doi: 10.1681/ASN.2006050445. Epub 2007 Apr 4. J Am Soc Nephrol. 2007. PMID: 17409317 Clinical Trial.
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators. Keane WF, et al. Among authors: shahinfar s. Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. doi: 10.2215/CJN.01381005. Epub 2006 May 17. Clin J Am Soc Nephrol. 2006. PMID: 17699284
104 results